All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Turbine and AstraZeneca partner for ADC discovery
The partnership will leverage Turbine’s platform and its capacity to streamline the ADC discovery process.
FDA approves Celltrion’s Eydenzelt for eye diseases
Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron Pharmaceuticals and Bayer.
Synaffix and Qurient enter licensing deal for dual-payload ADC
The collaboration will combine Synaffix’s exatecan-based tech with Qurient’s CDK7 inhibitor for solid tumour treatments.
FDA approves Lilly’s Inluriyo to treat advanced breast cancer
The approval was based on results from the Phase III EMBER-3 trial in 256 patients.
Moderna opens UK vaccine manufacturing facility
MITC will manufacture vaccines for respiratory illnesses, supporting the National Health Service’s vaccination programmes.
Sanofi announces $625m to venture capital arm
Sanofi Ventures is targeting early-stage and emerging opportunities in healthcare.
TegMine and Boehringer Ingelheim partner on cancer therapeutics
The partnership will initially target a clinically validated antigen and may expand to two additional targets.
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA
Enhertu was developed by Daiichi Sankyo and is co-commercialised with AstraZeneca.
Merck and Siemens extend digital transformation partnership in life sciences
The two companies will leverage automation, data and AI to streamline drug discovery, development and manufacturing.
Ionis and Sobi’s Tryngolza gains approval in EU for FCS treatment
Tryngolza is designed to reduce the production of apoC-III, a protein involved in triglyceride metabolism.